SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
SANOFI-AVENTIS

BRIEF

published on 12/04/2025 at 11:05, 18 hours 19 minutes ago

Sanofi Completes Acquisition of Vicebio

Respiratory Viruses Sanofi Acquisition Molecular Clamp Vicebio Vaccine Vaccine Pipeline
PRESS RELEASE

published on 12/04/2025 at 11:00, 18 hours 24 minutes ago

Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio, enhancing its vaccine portfolio with a combination vaccine candidate for RSV and HMPV. The 'Molecular Clamp' technology expands vaccine design capabilities

Acquisition Sanofi Vaccine Candidate RSV Vicebio
BRIEF

published on 11/25/2025 at 07:05, 9 days 22 hours ago

Dupixent: a breakthrough in the treatment of chronic spontaneous urticaria in Europe

Innovative Treatment Sanofi Dupixent Regeneron Chronic Urticaria
PRESS RELEASE

published on 11/25/2025 at 07:00, 9 days 22 hours ago

Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron receive EU approval for Dupixent as targeted medicine for chronic spontaneous urticaria, significantly reducing itch and hives compared to placebo

Sanofi Dupixent EU Approval Regeneron Chronic Spontaneous Urticaria
PRESS RELEASE

published on 11/17/2025 at 18:15, 17 days 11 hours ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 11/14/2025 at 12:35, 20 days 16 hours ago

Green light for Sanofi's Teizeild in type 1 diabetes

Sanofi Type 1 Diabetes Teizeild CHAMP TN-10 Study
PRESS RELEASE

published on 11/14/2025 at 12:30, 20 days 16 hours ago

Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi's Teizeild recommended for EU approval for stage 2 type 1 diabetes based on positive CHMP opinion. TN-10 study shows Teizeild delays the onset of stage 3 T1D

Sanofi CHMP EU Approval Type 1 Diabetes Teizeild
BRIEF

published on 11/07/2025 at 14:05, 27 days 15 hours ago

Sanofi and Regeneron's Dupixent: Advances against allergic fungal rhinosinusitis

FDA Sanofi Dupixent Regeneron AFRS
PRESS RELEASE

published on 11/07/2025 at 14:00, 27 days 15 hours ago

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Sanofi and Regeneron announce positive results from Dupixent pivotal study in allergic fungal rhinosinusitis, with sBLA accepted for FDA priority review

FDA Sanofi Dupixent Regeneron AFRS
PRESS RELEASE

published on 10/24/2025 at 07:30, 1 month 11 days ago

Press release: Q3: continued sales and earnings progress

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 49 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 54 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 24 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 19 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 24 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 53 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 33 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 58 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 9 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 13 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 24 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 39 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 40 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 23 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE